The content on this site is intended for healthcare professionals only
Dr Sexl speaks with ecancer at EHA 23 about the findings linking CDK6 to p53 regulation and transcription in AML.
While CDK4/6 inhibitors are being pursued as regulators of the cell cycle in breast and ovarian cancers, Dr Sexl highlights that CDK4 alone is active as a regulator in AML.
Dr Sexl also spoke with ecancer about JAK pathways in B cell lymphoma, coming soon.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Relapsed refractory multiple myeloma
The evolving paradigm in management of Multiple Myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
